Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

Novo Nordisk A/S NVO

Healthcare — Drug Manufacturers General
Cash Flow Champion (5y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
24.48%

Capital & Financial Ratios

Market Cap
144,610.00
Revenue
51,459.47
Net Income
17,882.69
Free Cash Flow
7,610.53
Net Debt
14,205.51
Current Ratio
0.87
Debt/Equity
0.63
P/E ratio
10.57
P/S ratio
3.73
P/B ratio
5.57
Past 5Y EPS Growth
21.74%
This Y EPS Growth
(6.06%)
Next Y EPS Growth
(2.47%)
Next 5Y EPS Growth
(0.04%)
in millions of $

Dividends

Payout Ratio
0.41
Annual Dividend Rate
1.03
Annual Dividend Yield
1.36%
total individual payouts
2026 1.80
—
—
2025 1.73
—
—
2024 1.45
—
—
2023 1.03
—
—
2022 0.80
—
—
2021 0.74
—
—
2020 0.65
—
—
2019 0.61
—
—
2018 0.63
—
—
2017 0.57
—
—
2016 0.48
—
—
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 4,729.75 4,731.93 5,093.70 7,598.26
Receivables 10,927.90 12,675.03 13,502.76 16,884.47
Inventory 4,618.96 5,923.11 7,512.92 7,990.37
Other — — — —
20,276.60 23,330.06 26,109.38 32,473.10
2023 2024 2025 Q'26
Payables 3,717.99 4,182.67 2,991.36 2,270.36
ST’ Debt 940.61 1,901.39 1,819.37 2,852.62
Other 18,942.07 24,048.69 26,566.16 28,894.76
24,633.91 31,541.56 32,651.08 37,201.32
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 15,162.48 12,212.73 — —
—
’25 11,018.08 11,689.95 11,741.24 12,343.02
46,792.29
’24 9,514.81 9,821.06 10,511.24 12,261.32
42,108.43
’23 7,690.19 7,933.23 8,574.73 9,526.16
33,724.30
’22 6,338.28 5,900.90 6,165.08 6,652.44
25,056.69
’21 5,479.63 5,355.95 5,649.65 5,916.05
22,401.28
’20 5,003.34 4,431.89 4,855.54 5,157.36
19,448.13
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 3,771.55 8,564.88 — —
—
’25 3,469.79 6,473.90 7,514.55 573.80
18,032.04
’24 2,084.12 7,268.98 6,664.43 1,522.84
17,540.36
’23 4,296.20 4,234.73 5,975.20 1,307.32
15,813.44
’22 3,556.77 3,242.45 2,913.43 1,457.75
11,170.40
’21 1,824.44 4,093.84 3,283.23 (451.00)
8,750.50
’20 1,478.77 3,583.35 3,067.18 (170.41)
7,958.89
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 1,886.25 6,585.08 — —
—
’25 1,411.71 3,838.03 4,961.69 (5,822.49)
4,388.93
’24 772.41 5,370.44 4,752.52 (794.81)
10,100.56
’23 3,604.37 3,197.31 4,425.27 (1,061.22)
10,165.74
’22 3,288.35 2,888.11 2,375.32 529.60
9,081.37
’21 1,581.45 3,788.44 3,027.35 (821.69)
7,575.55
’20 1,224.28 3,381.44 2,083.41 (2,111.99)
4,577.16
in millions of $

EPS

Mar Jun Sep Dec Year
’26 1.71 0.74 — —
—
’25 0.92 0.91 0.70 0.94
3.49
’24 0.83 0.65 0.90 0.91
3.28
’23 0.64 0.63 0.73 0.71
2.70
’22 0.47 0.42 0.43 0.42
1.73
’21 0.44 0.43 0.42 0.37
1.65
’20 0.38 0.34 0.35 0.32
1.38

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

3.2
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 45.76 65.05 81.50 43.08 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 67.93 105.69 148.15 93.80 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 55,185 63,370 77,349 69,505 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.45 0.53 0.54 0.67 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 25,056.69 33,724.30 42,108.43 46,792.29 — — —
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 83.92% 84.60% 84.67% 80.98% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,779.18 15,198.67 18,442.70 19,763.76 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.03% 45.07% 43.80% 42.24% — — —
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7,862.34 12,150.77 14,643.26 15,508.51 — — —
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,042.46 1,366.77 2,770.52 3,328.08 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 5.53 7.52 9.45 10.53 — — —
Revenue/Sh
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.74 2.71 3.29 3.49 — — —
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.47 3.53 3.94 4.06 — — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.46) (1.26) (1.67) (3.07) — — —
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.00 2.27 2.27 0.99 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.61 3.45 4.67 6.61 — — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,530.60 4,482.80 4,453.90 4,443.00 — — —
Shares
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 39.47 37.75 26.15 14.66 — — —
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.38 13.57 9.10 4.83 — — —
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 26.24 29.58 18.41 7.69 — — —
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 12.38 13.55 9.34 5.15 — — —
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 34.16 44.95 38.94 54.86 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11,170.40 15,813.44 17,540.36 18,032.04 — — —
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (2,089.03) (5,647.70) (7,439.80) (13,643.11) — — —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9,081.37 10,165.74 10,100.56 4,388.93 — — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1,804.83) (4,357.31) (8,211.50) (6,541.70) — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,651.01 3,921.27 14,904.12 19,827.04 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (73.21) (808.47) 10,172.19 14,733.34 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11,821.62 15,472.66 20,805.47 29,378.71 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.15% 30.44% 25.87% 20.71% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.35% 63.48% 37.55% 27.38% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 68.14% 89.04% 80.73% 61.81% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

Novo Nordisk (NVO) has powered through a remarkable growth phase, with revenue exploding from $16.6 billion in 2016 to a projected $42.1 billion in 2024—a 20%+ CAGR driven by GLP-1 leaders Ozempic and Wegovy amid surging obesity and diabetes demand. Metrics shine: revenue per employee up 38% to $544,000, EPS at a 25% CAGR to $3.29, and gross margins steady at 83-85%, underscoring scalable dominance with over 50% semaglutide market share. Yet, the stock has cratered 67% from 2024 highs, trading near 2020 levels despite tripled earnings, as capex doubles to $7.4 billion for supply ramps and debt surges to $14.9 billion.

Profitability remains elite—ROE at 81%, FCF/share at $2.27—mirroring past pharma booms like 1990s Merck, but headwinds mount: FCF/share halving in 2025, negative working capital at -$8.2 billion, and intensifying competition from Eli Lilly’s Mounjaro. Valuations have normalized (PE 26x, PS 9.1x) post-euphoria, decoupling from fundamentals in a GLP-1 fatigue reminiscent of biotech cycles.

Analysts forecast 11% revenue growth to $46.8 billion in 2025, with catalysts like Wegovy patient ramps to 20-30 million, CagriSema data, and a $100 billion obesity market by 2030—but risks include patent cliffs post-2032, regulatory scrutiny, and 10-15% drawdown potential. This 67% correction offers a historical entry for 15-20% annualized returns through 2030, warranting selective accumulation below mean targets amid execution tests.

Read full commentary →

Novo Nordisk A/S (NVO) Latest News

News by impact score

Fine-tune

18 Sep

4 247wallst.com, 5:15 PM
Eli Lilly weighs a two-drug obesity regimen against its $1 trillion valuation while competing directly with Novo Nordisk in the weight-loss market. Lilly's dual-drug obesity candidate heightens competitive pressure and shifts market share expectations for Novo Nordisk.

4 , 12:57 PM
Novo Nordisk CEO stated the company must rethink its obesity strategy. CEO signals potential overhaul of core obesity business affecting long-term trajectory.

4 www.barchart.com, 12:52 PM
Novo Nordisk builds strong base to address unmet needs in diabetes and obesity drugs. Strategic base building in core diabetes and obesity areas drives major shifts in Novo Nordisk trajectory.

3 , 12:09 PM
Novo Nordisk's Denecimig receives CHMP positive opinion for hemophilia A treatment in the European Union. CHMP nod advances Denecimig toward EU approval and supports NVO hemophilia portfolio expansion.

3 , 6:36 AM
Novo Nordisk receives positive CHMP opinion in Europe for once-weekly Sogroya (somapacitan) in children with idiopathic short stature. Positive CHMP opinion advances potential European approval of Sogroya for pediatric idiopathic short stature, expanding growth hormone market reach.

17 Sep

4 , 7:18 PM
CHMP grants green light to FREHEMGO for Novo Nordisk, prompting assessment of whether the stock trades as a bargain. CHMP approval for FREHEMGO opens major revenue opportunities and shifts competitive positioning for Novo Nordisk.

4 , 10:14 AM
CHMP recommends EU approval of Novo Nordisk's FREHEMGO® (denecimig) for haemophilia A as the first factor VIIIa mimetic with monthly, biweekly or weekly dosing in a pre-filled pen. CHMP recommendation advances novel haemophilia therapy toward EU launch, supporting revenue growth and market positioning.

4 www.fool.com, 4:35 AM
Rising demand for GLP-1 weight-loss drugs strengthens Eli Lilly's market position against Novo Nordisk's Ozempic and Wegovy, boosting Lilly's sales and investor outlook in the diabetes and obesity treatment space. Positive momentum for Eli Lilly directly heightens competitive pressure on Novo Nordisk's core GLP-1 products and future revenue trajectory.

3 , 7:37 PM
Novo Nordisk discontinues two additional heart drug trials. Trial terminations signal pipeline setbacks that may limit future product options and growth areas.

3 stocktwits.com, 2:33 PM
European committee backs Novo Nordisk haemophilia pen, lifting NVO stock 4%. Positive regulatory step for haemophilia product drives noticeable but limited stock reaction outside core diabetes business.

3 , 11:46 AM
Study finds Novo Nordisk and Eli Lilly weight-loss drugs remain effective at smaller doses. Lower-dose efficacy may improve accessibility and support ongoing adoption without shifting core market dynamics.

3 , 10:34 AM
Novo Nordisk partners with Anthropic to apply AI for accelerating drug discovery. AI partnership may boost drug discovery pipeline but effects remain incremental amid existing operations.

3 , 9:56 AM
Novo Nordisk signs licensing deal with Orbis Medicines worth up to $1.4 billion. Deal adds pipeline options at standard partnership scale without immediate core revenue or market shift.

3 www.fool.com, 7:05 AM
Wall Street analysts forecast a major rebound for Viking Therapeutics based on strong optimism about its pipeline and market prospects in obesity treatments. Viking Therapeutics rebound signals rising competition that may moderately pressure Novo Nordisk market share and growth in weight-loss drugs.

3 , 7:00 AM
Novo Nordisk enters multi-target drug discovery partnership with Orbis Medicines valued up to USD 1.4 billion. Partnership adds pipeline expansion via milestone-based R&D deal but lacks immediate product or revenue impact.

16 Sep

4 , 12:33 PM
Novo Nordisk partners with Anthropic to integrate AI across operations, targeting billions in cost savings for drug development and production. Novo Nordisk's Anthropic deal represents a major strategic move to embed AI for substantial efficiency gains and competitive shifts.

4 www.fool.com, 12:20 PM
Novo Nordisk confronts intensifying competition in the GLP-1 market from new entrants, raising uncertainty over its market share, growth trajectory, and positioning within five years. Rising GLP-1 competition represents a major market dynamic shift capable of significantly altering Novo Nordisk's trajectory and investor sentiment.

4 , 10:16 AM
Novo Nordisk enters major AI deal with world's most valuable AI company. Major AI partnership signals strategic move likely to boost innovation and alter competitive positioning.

4 , 8:40 AM
Novo Nordisk partners with Anthropic to accelerate drug discovery through AI applications. AI partnership targets core drug development pipeline and can materially speed innovation and competitive positioning.

4 , 8:00 AM
Novo Nordisk partners with Anthropic to apply Claude AI for advancing drug discovery. AI partnership represents major strategic move to accelerate drug discovery and pipeline innovation.

4 www.biopharmadive.com, 7:10 AM
Novo Nordisk plans to integrate Anthropic AI models into its operations to accelerate drug development. AI integration targets core drug development to potentially speed innovation and reshape competitive positioning.

3 , 5:06 PM
Novo Nordisk shares declined after Anthropic's Claude AI entered drug development, signaling emerging competition in pharmaceutical innovation for the company's core operations. AI entry into drug development creates moderate future competitive pressure on Novo Nordisk without immediate fundamental disruption.

3 www.barchart.com, 3:42 PM
Novo Nordisk partners with Anthropic to apply AI in drug discovery efforts. AI partnership may support pipeline innovation but does not shift core operations or near-term performance.

3 , 3:08 PM
Novo Nordisk partners with Anthropic to accelerate drug discovery and development. AI collaboration targets R&D efficiency in core operations but remains early-stage without immediate financial or market shifts.

3 , 2:27 PM
Critics warn of AI-driven disasters while Anthropic and Novo Nordisk A/S pursue AI initiatives expecting beneficial results instead. AI partnership signals potential efficiency gains in drug discovery but lacks immediate regulatory or financial triggers.

3 stocktwits.com, 9:05 AM
Novo Nordisk partners with Anthropic to deploy Claude AI for accelerating drug discovery and development timelines. AI deployment in discovery processes may modestly speed innovation and affect competitive positioning over time.

3 investorshub.advfn.com, 8:36 AM
Novo Nordisk partners with Anthropic to apply AI to drug discovery and research. AI partnership supports incremental gains in research capabilities without major immediate shifts in operations or market position.

3 stocktwits.com, 6:44 AM
Novo Nordisk will present new data on its blockbuster Wegovy obesity pill at a European conference while rival Eli Lilly prepares its own obesity treatment updates. Conference data on Wegovy may shift short-term sentiment and competitive positioning versus Eli Lilly but is unlikely to alter long-term trajectory.

3 , 3:00 AM
Novo Nordisk will present real-world and clinical data on Wegovy pill and cardiometabolic pipeline progress with next-generation amylin treatments at EASD 2026. Pipeline presentations signal moderate innovation potential in obesity and cardiometabolic therapies.

15 Sep

3 247wallst.com, 12:20 PM
Novo Nordisk expands obesity drug to children, yet market shows hesitation on adoption. Pediatric expansion opens new revenue segment but faces adoption limits that moderate overall trajectory shift.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us